Close Menu

Biomarker Discovery & Validation

News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.

The companies aim to identify biomarkers that can be used to diagnose early-onset Parkinson's disease, as well as track disease progression.

The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.

Qiagen will develop T cell-based lab tests to detect prior exposure to SARS-CoV-2 using discoveries from TScan's target discovery platform.

The test uses the sTRA biomarker to differentiate between different subtypes of pancreatic cancer, including those that are resistant to chemotherapy.

The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.